All payments made in the preview are in test mode. Read more
Sign in
Back to Atlas
CTransientPrescription / clinician-supervised
CMP-0457
Approved drug

Tadalafil

Vascular / Performance

Improves erectile function and pulmonary/vascular hemodynamics; may support exercise tolerance in specific vascular contexts

Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type
Small molecule drug
Primary mechanism
PDE5 inhibition increasing cGMP signaling
Primary market use
ED / PAH / vascular performance

Pharmacology

Molecular weight (Da)
389.41
Oral bioavailability
Oral; absolute F not determined
Half-life
~17.5 h
Route tags
Oral
Evidence level
Approved
Clinical status
Approved drug
Value-for-money score
8 / 10

Reported protocol signal

Prescription use; common ED dosing 5 mg daily or 10–20 mg as needed.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

High value due oral route, long duration, generic availability, and clear QoL benefit in indicated use

Educational and organizational assistant matrix. Not medical advice.

BioChrysalis Atlas is an educational, organizational, and tracking asset. It does not provide medical advice, diagnosis, treatment, prescriptions, or individualized dosing instructions. Compound profiles, protocol notes, and dosage fields summarize publicly discussed or source-listed reference patterns and are not recommendations. Consult a qualified healthcare professional before starting, stopping, or modifying any compound, medication, or supplement protocol.

© BioChrysalis · Evolve · Ascend · Transcend